NCT01028521

First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: CellMed AG, a subsidiary of BTG plc. · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of single ascending doses of CM3.1-AC100 in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	CM3.1-AC100	Solution for sc injection, single ascending doses
DRUG	Placebo	Solution for sc injection

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2009-12-09
• Last updated: 2010-07-15

Locations

1 site across 1 country: Germany